标题
Clinical Trials for Ductal Carcinoma In Situ of the Breast
作者
关键词
Ductal carcinoma in situ, DCIS, Clinical trial, Breast cancer, Surgery, Radiotherapy, Active surveillance
出版物
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
Volume -, Issue -, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-09-12
DOI
10.1007/s10911-018-9413-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies
- (2018) E. Rakovitch et al. BREAST CANCER RESEARCH AND TREATMENT
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Abstract GS5-05: Primary endocrine therapy for ER-positive ductal carcinoma in situ (DCIS) CALGB 40903 (Alliance)
- (2018) ES Hwang et al. CANCER RESEARCH
- Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal CarcinomaIn Situ—A Nested Case–Control Study
- (2018) Lindy L. Visser et al. CLINICAL CANCER RESEARCH
- Identifying a subset of patients with DCIS who have a low likelihood of residual disease at surgical excision following a core needle biopsy
- (2017) Brittany L. Murphy et al. JOURNAL OF SURGICAL ONCOLOGY
- Loss of Anti-HER-3 CD4+ T-Helper Type 1 Immunity Occurs in Breast Tumorigenesis and is Negatively Associated with Outcomes
- (2016) Megan Fracol et al. ANNALS OF SURGICAL ONCOLOGY
- The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis
- (2016) M. Luke Marinovich et al. ANNALS OF SURGICAL ONCOLOGY
- Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?
- (2016) Nikiforita Poulakaki et al. BREAST
- Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer
- (2016) Yukiko Tabuchi et al. BREAST CANCER RESEARCH AND TREATMENT
- Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2 pos DCIS Independent of Route: Results of Randomized Selection Design Trial
- (2016) Lea Lowenfeld et al. CLINICAL CANCER RESEARCH
- The development and use of the E75 (HER2 369–377) peptide vaccine
- (2016) Guy T Clifton et al. Future Oncology
- Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial
- (2016) John F Forbes et al. LANCET
- Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial
- (2016) Richard G Margolese et al. LANCET
- Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study
- (2016) Stephen W Duffy et al. LANCET ONCOLOGY
- Alternate dosing schedules for cancer chemopreventive agents
- (2016) Matteo Lazzeroni et al. SEMINARS IN ONCOLOGY
- Growing Use of Mastectomy for Ductal Carcinoma-In Situ of the Breast Among Young Women in the United States
- (2015) Charles E. Rutter et al. ANNALS OF SURGICAL ONCOLOGY
- Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base
- (2015) Meghan R. Flanagan et al. ANNALS OF SURGICAL ONCOLOGY
- A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone
- (2015) Eileen Rakovitch et al. BREAST CANCER RESEARCH AND TREATMENT
- Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation
- (2015) Oukseub Lee et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The LORIS Trial: Addressing Overtreatment of Ductal Carcinoma In Situ
- (2015) A. Francis et al. CLINICAL ONCOLOGY
- Addressing overtreatment of screen detected DCIS; the LORIS trial
- (2015) Adele Francis et al. EUROPEAN JOURNAL OF CANCER
- Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study
- (2015) Lotte E. Elshof et al. EUROPEAN JOURNAL OF CANCER
- RTOG 9804: A Prospective Randomized Trial for Good-Risk Ductal Carcinoma In Situ Comparing Radiotherapy With Observation
- (2015) Beryl McCormick et al. JOURNAL OF CLINICAL ONCOLOGY
- Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study
- (2015) Lawrence J. Solin et al. JOURNAL OF CLINICAL ONCOLOGY
- Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ
- (2015) Mathias Worni et al. JNCI-Journal of the National Cancer Institute
- Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ
- (2015) Yasuaki Sagara et al. JAMA Surgery
- Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ
- (2015) Mathias Worni et al. JNCI-Journal of the National Cancer Institute
- Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ
- (2015) Steven A. Narod et al. JAMA Oncology
- A Randomized Phase II Presurgical Trial of Transdermal 4-Hydroxytamoxifen Gel versus Oral Tamoxifen in Women with Ductal Carcinoma In Situ of the Breast
- (2014) O. Lee et al. CLINICAL CANCER RESEARCH
- A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study
- (2013) A. DeCensi et al. ANNALS OF ONCOLOGY
- Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43
- (2013) Kalliopi P. Siziopikou et al. BREAST CANCER RESEARCH AND TREATMENT
- A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast
- (2013) L. J. Solin et al. JNCI-Journal of the National Cancer Institute
- Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24
- (2012) D. Craig Allred et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Management Factors Contribute to the Decision for Contralateral Prophylactic Mastectomy
- (2011) Tari A. King et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS
- (2011) I. L. Wapnir et al. JNCI-Journal of the National Cancer Institute
- Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast
- (2010) Henry M. Kuerer et al. CANCER
- Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis
- (2010) K. Kerlikowske et al. JNCI-Journal of the National Cancer Institute
- Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
- (2010) Jack Cuzick et al. LANCET ONCOLOGY
- Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ
- (2009) Yunn-Yi Chen et al. BMC CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More